Pliant Therapeutics, Inc. (PLRX) Tops Q2 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/21/2026
- Nasdaq leads gains as SpaceX, Super Micro results improve AI appetite
- SpaceX, Tesla shares rise after Musk says committees exploring possible merger
- Brent falls as Iran's president discusses mediation with Pakistani army chief
- Nvidia’s Huang highlights AI benefits in Berlin speech amid wider European tour
- AI bubble about to burst? Not yet, Yardeni says
Tweet
Share
E-mailGet Alerts PLRX Hot Sheet
Join SI Premium – FREE
Pliant Therapeutics, Inc. (NASDAQ: PLRX) reported Q2 EPS of ($0.70), $0.01 better than the analyst estimate of ($0.71). Revenue for the quarter came in at $250 thousand versus the consensus estimate of $1.21 million.
For earnings history and earnings-related data on Pliant Therapeutics, Inc. (PLRX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Netflix shares fall over 5% premarket on soft current-quarter revenue guidance
- First Community Corp. (FCCO) Tops Q3 EPS by 5c
- Pliant Therapeutics Appoints Craig Blanchette, Ph.D., as Senior Vice President, Research (siRNA)
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
